SciRAP criteria for assessing reporting quality of *in vivo* toxicity studies

Test compound and controls
1. The chemical name, ID or CAS-number of the test compound was given.
2. The purity of the test compound was stated or is traceable according to information given regarding manufacturer and lot/batch number. In case of mixtures, the composition of different constituents was stated.
3. The vehicle was described.
4. It was stated that a negative control group was included.
Animal model and housing conditions
5. The animal model (species, strain, age or life stage and sex) was described.
6. The method for individual identification of animals was described.
7. The housing temperature was stated.
8. The relative humidity was stated.
9. The light-dark cycle was described.
10. The number of animals per sex in each cage was stated.
11. The cage materials were described.
12. Any materials used for physical enrichment were described.
13. Water bottle materials were described.
14. The bedding material used was described.
15. The type and source of feed were reported.
16. The source of drinking water was reported.
Dosing and administration of the test compound
17. The administered dose levels or concentrations were stated.
18. The method for allocating animals to different treatments was stated.
19. The total number of animals per dose group was stated.
20. The route of administration was stated.
21. The sex and age (or life stage) of the animals at start of dosing was stated or is obvious from the information given, e.g. “pregnant rats were used” is enough information that animals are female and sexually mature/adult.

22. The frequency and duration of dosing/administration of the test compound was stated.
Data collection and analysis
23. The test and/or analytical methods used were sufficiently described to allow for evaluation of the reliability of results.
24. The method for allocating animals to different tests and measurements (e.g. tissue collection or evaluation of functional or behavioural endpoints) was stated.
25. The sex, age and number of animals per dose group subjected to separate tests and measurements was stated.
26. The statistical methods and software used were described.
27. The statistical unit, e.g. the individual or the litter, was stated.
28. All results for the investigated endpoints were reported. The most critical results were presented in tables and figures, including description of variation and statistically significant results.
Funding and competing interests
29. The funding sources for the study were stated.
30. Any competing interests were disclosed or it was explicitly stated that the authors did not have any competing interests.